These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24619073)

  • 1. Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models.
    Cao S; Durrani FA; Tóth K; Rustum YM
    Br J Cancer; 2014 Apr; 110(7):1733-43. PubMed ID: 24619073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
    Cao S; Durrani FA; Rustum YM
    Clin Cancer Res; 2004 Apr; 10(7):2561-9. PubMed ID: 15073137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent.
    Azrak RG; Cao S; Pendyala L; Durrani FA; Fakih M; Combs GF; Prey J; Smith PF; Rustum YM
    Biochem Pharmacol; 2007 May; 73(9):1280-7. PubMed ID: 17239826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.
    Chintala S; Tóth K; Cao S; Durrani FA; Vaughan MM; Jensen RL; Rustum YM
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):899-911. PubMed ID: 20066420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.
    Bhattacharya A; Tóth K; Durrani FA; Cao S; Slocum HK; Chintala S; Rustum YM
    Neoplasia; 2008 Aug; 10(8):857-65. PubMed ID: 18670644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors.
    Azrak RG; Yu J; Pendyala L; Smith PF; Cao S; Li X; Shannon WD; Durrani FA; McLeod HL; Rustum YM
    Mol Cancer Ther; 2005 May; 4(5):843-54. PubMed ID: 15897249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiogenesis.
    Yin MB; Li ZR; Tóth K; Cao S; Durrani FA; Hapke G; Bhattacharya A; Azrak RG; Frank C; Rustum YM
    Oncogene; 2006 Apr; 25(17):2509-19. PubMed ID: 16518418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
    Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic antitumor activity of capecitabine in combination with irinotecan.
    Cao S; Durrani FA; Rustum YM
    Clin Colorectal Cancer; 2005 Jan; 4(5):336-43. PubMed ID: 15663838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors.
    Fakih M; Cao S; Durrani FA; Rustum YM
    Clin Colorectal Cancer; 2005 Jul; 5(2):132-5. PubMed ID: 16098255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New options in patients with metastatic cancer of the colon already treated: platinum salts].
    Cartei G
    Tumori; 2000; 86(3 Suppl):S42-8. PubMed ID: 10969617
    [No Abstract]   [Full Text] [Related]  

  • 12. Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients.
    Cals L; Rixe O; François E; Favre R; Merad L; Deplanque G; Laadem A; Juin P; Bereder JM; Bernardini D; Herait P
    Ann Oncol; 2004 Jul; 15(7):1018-24. PubMed ID: 15205194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study.
    Tsuji K; Yasui H; Onozawa Y; Boku N; Doyama H; Fukutomi A; Yamazaki K; Machida N; Todaka A; Taniguchi H; Tsushima T; Yokota T
    Jpn J Clin Oncol; 2012 Aug; 42(8):686-90. PubMed ID: 22693245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts.
    Na YS; Kim SM; Jung KA; Yang SJ; Hong YS; Ryu MH; Ro S; Cho DH; Kim JC; Jin DH; Lee JS; Kim TW
    Oncol Rep; 2010 Dec; 24(6):1509-14. PubMed ID: 21042746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.
    Ulrich-Pur H; Kornek GV; Fiebiger W; Gedlicka C; Raderer M; Lenauer A; Depisch D; Lang F; Pidlich J; Scheithauer W
    Ann Oncol; 2001 Sep; 12(9):1269-72. PubMed ID: 11697839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.
    Sheikh HY; Valle JW; Palmer K; Sjursen A; Craven O; Wilson G; Swindell R; Saunders MP
    Br J Cancer; 2007 Jan; 96(1):38-43. PubMed ID: 17213824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical combination therapy of thiarabine plus various clinical anticancer agents.
    Waud WR; Gilbert KS; Secrist JA
    Nucleosides Nucleotides Nucleic Acids; 2012; 31(8):630-46. PubMed ID: 22908953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs.
    Bhattacharya A; Seshadri M; Oven SD; Tóth K; Vaughan MM; Rustum YM
    Clin Cancer Res; 2008 Jun; 14(12):3926-32. PubMed ID: 18559614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
    Vasile E; Masi G; Fornaro L; Cupini S; Loupakis F; Bursi S; Petrini I; Di Donato S; Brunetti IM; Ricci S; Antonuzzo A; Chiara S; Amoroso D; Andreuccetti M; Falcone A
    Br J Cancer; 2009 Jun; 100(11):1720-4. PubMed ID: 19436300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
    Delaunoit T; Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Findlay BP; Thomas SP; Salim M; Schaefer PL; Stella PJ; Green E; Mailliard JA
    Cancer; 2004 Nov; 101(10):2170-6. PubMed ID: 15470715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.